Stock Analiz

Rani Therapeutics Holdings, Inc. RANI

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$0.53Market cap $61M
Open the interactive analysis →

Rani Therapeutics Holdings, Inc. (RANI) is a healthcare company listed in the US with a market value of about $61M. In the twelve months to September 30, 2026 it had revenue of $7M and net income of -$32M, a net margin of -493.0%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 29% a year, a 5-year average ROIC of -105%.

About Rani Therapeutics

Rani Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $462000 in 2020 to $2M in 2025, growth of about 28.7% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 178% over three years (dilution for shareholders). It spends 1237% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S9.2
P/B1.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-38.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)58.9%
Revenue growth (5 yrs, per year)28.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1681.2%
ROIC (5-yr avg.)-104.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$7M$2M$1M$0$0$3M$462000
Net income-$32M-$30M-$30M-$34M-$31M-$8M-$17M
Free cash flow-$23M-$19M-$36M-$52M-$48M-$33M-$16M
EPS (diluted)$-0.07$-0.45$-1.05$-1.33$-1.28$-0.43—
Net margin-493.0%-1817.1%-2920.0%——-306.6%-3615.4%
ROIC—-81.1%-131.3%-151.7%-73.8%-86.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $7.20, 1268% above the current price; targets range from $5.00 to $11.00; the consensus rating is “Strong buy”; expected EPS is $-0.17 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Rani Therapeutics pay a dividend?

Not currently.

Is Rani Therapeutics a good stock to buy?

We do not give buy or sell advice. Rani Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.